Image Courtesy of Oxford Properties Group

What: CRISPR Therapeutics manufacturing facility
Where: 33 New York Ave., Framingham
Owner: Oxford Properties Group
Built: 2020-2022 

CRISPR Therapeutics’ new Framingham manufacturing facility was recognized for innovation in a recent awards category by the International Society of Pharmaceutical Engineering. 

The facility was designed by architects TRIA with multiple independent production suites, each of which is capable of producing different products at different stages of development.  

The project team included DPS Group, architect TRIA Design, owner’s representative Leggat McCall Properties, construction manager and general contractor Commodore Builders and structural engineer Pare Corp. 

They Said It: 

“Driven by our unwavering commitment to address patient needs, we are proud to be recognized by ISPE as 2022 Facility of the Year in Innovation for our state-of-the-art manufacturing facility in Framingham, Massachusetts that has been innovatively designed with flexibility and scale in mind.” 

— Stephen Kennedy, head of tech operations, CRISPR Therapeutics